Chapter 37 — Quiz

DataField.Dev

Chapter 37 — Quiz

Twenty-two items. Work them without the chapter open, then check the key. Items 18–22 are short answer; there is no single wording that counts as correct, and the key gives what a good answer contains.

1. How many ratings does this book issue in total, and how do they divide?

(a) 140 total: 126 molecule/indication and 14 claim form
(b) 154 total: 140 molecule/indication and 14 claim form
(c) 154 total: 144 molecule/indication and 10 claim form
(d) 168 total: 154 molecule/indication and 14 claim form

2. A rating in this book attaches to:

(a) a molecule
(b) a claim, specified by population and endpoint
(c) a product
(d) a therapeutic class

3. Which ❌ describes the stronger state of knowledge?

(a) Evidence absent — the trials were never run
(b) Evidence present and negative — the trials ran and answered no
(c) They are equivalent
(d) It depends on the compound's mechanism

4. BPC-157 for tendon and soft-tissue healing is an example of:

(a) evidence present and negative
(b) evidence absent
(c) a split rating
(d) NOT RATED

5. Nesiritide for death or rehospitalization in acute decompensated heart failure is an example of:

(a) evidence present and negative
(b) evidence absent
(c) a surrogate endpoint being validated
(d) a frontier claim

6. How many claims in this book are recorded as NOT RATED?

(a) one
(b) two
(c) four
(d) ten

7. Where do all the NOT RATED entries appear?

(a) scattered evenly across the book
(b) in Part III, among the enhancement compounds
(c) in Part VIII, among the claims about society
(d) in the claim-form table only

8. In the Chapter 44 obesity-policy claim, the word that makes it unrateable is:

(a) "society"
(b) "obesity"
(c) "primarily"
(d) "pharmacologically"

9. NOT RATED is best described as:

(a) a fifth tier below ❌
(b) a synonym for 🔬
(c) a statement that the claim is not the kind evidence settles
(d) a placeholder pending more data

10. The overall distribution of the 154 ratings is:

(a) 54 ✅, 26 ⚠️, 50 ❌, 10 🔬, 10 split, 4 NOT RATED
(b) 50 ✅, 34 ⚠️, 56 ❌, 10 🔬, 4 NOT RATED
(c) 26 ✅, 54 ⚠️, 50 ❌, 20 🔬, 4 NOT RATED
(d) 54 ✅, 50 ⚠️, 26 ❌, 10 🔬, 10 split, 4 NOT RATED

11. According to §37.8, ✅ ratings cluster:

(a) among compounds with the most elegant mechanisms
(b) among compounds dispensed by prescription, generally after regulatory approval
(c) among the newest compounds
(d) randomly with respect to how a compound is sold

12. The clustering of ❌ among direct-to-consumer compounds is primarily a fact about:

(a) peptides
(b) consumers
(c) which peptides get studied, and therefore who pays for trials
(d) regulatory hostility to peptides

13. A split rating such as ⚠️/❌ most commonly means:

(a) the raters could not agree
(b) a modest version of the claim is supported and the strong marketing version is not
(c) the compound works in half of patients
(d) the rating is provisional

14. Which block of the master table contains the highest concentration of split ratings?

(a) Metabolic and weight
(b) Oncology
(c) Cosmetic and topical
(d) Cardiovascular

15. Which kind of ✅ is most durable over time?

(a) ✅ resting on a surrogate endpoint
(b) ✅ resting on a hard clinical outcome in an adequately powered randomized trial
(c) ✅ resting on a well-characterized mechanism
(d) ✅ resting on decades of clinical experience without trials

16. Per Chapter 9 and §37.9, the commoner direction of movement for a ⚠️ resting on a single phase 2 result is:

(a) upward to ✅, because early results usually replicate
(b) downward to ❌, because effects usually shrink in larger, longer, better-blinded studies
(c) sideways to 🔬
(d) unpredictable in principle

17. Semaglutide occupies how many rows in the master table, resolving to how many distinct claims, across how many tiers?

(a) three rows, three claims, one tier
(b) six rows, six claims, two tiers
(c) ten rows, eight distinct claims, four tiers
(d) ten rows, ten claims, one tier

Short answer

18. Growth hormone appears twice in the master table with opposite ratings. Quote the phrase in the population field that produces the difference, and name one other pair in the same block that works the same way.

19. Explain, in three sentences, why "third-party tested" is rated ❌ even though testing is better than no testing.

20. A friend says: "There's no evidence against it, so it might work." Name the two things wrong with using that as an argument, and the one thing right about it as a logical point.

21. §37.10 says neither generous drift nor severe drift is more respectable. Explain why, and say which of the two is harder to detect in yourself and why.

22. In one sentence each, state what a rating in this book never tells you about (i) safety and (ii) you personally.

Answer key

**1. (b)** 154 total: 140 molecule/indication and 14 claim form. Chapters 37 and 40 contribute none — they restate ratings rather than issue them. **2. (b)** A claim, specified by population and endpoint. Rule 1 of §37.2. "Semaglutide" is not a claim; "semaglutide reduces major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, without diabetes" is. **3. (b)** Evidence present and negative. Trials that ran and answered no represent knowledge that was paid for. Trials that never ran represent an empty page. Readers routinely invert this. **4. (b)** Evidence absent. As of this writing there is no completed, peer-reviewed, randomized controlled human trial of BPC-157 in the published literature (Chapters 5 and 17). **5. (a)** Evidence present and negative. Approved on hemodynamic surrogates and short-term symptom measures; a subsequent randomized placebo-controlled outcome trial of roughly 7,100 patients found no meaningful effect on death or rehospitalization (Chapter 28). **6. (c)** Four. **7. (c)** Part VIII. This is the part that rates claims about society rather than about molecules, and it is where the system reaches the edge of its domain. **8. (c)** "Primarily." It encodes a judgment about how a society allocates attention between two approaches that are not mutually exclusive. No trial has "primarily" as an endpoint. **9. (c)** A statement that the claim is not the kind evidence settles. It is not a tier, and it is not 🔬 — 🔬 says *the answer is coming*, NOT RATED says *this instrument does not produce that kind of answer*. **10. (a)** 54 ✅, 26 ⚠️, 50 ❌, 10 🔬, 10 split, 4 NOT RATED. Note that ✅ outnumbers ❌ by four, which is a real direction and a margin too small to argue from — see §37.8. **11. (b)** Prescription compounds, generally after regulatory approval, in defined populations. **12. (c)** Which peptides get studied — which is a question about who funds trials. See Chapter 38 §38.10. It is not evidence that unstudied compounds are worse; it is evidence that they are unstudied. **13. (b)** A modest version supported, the strong marketing version not. Eight of the ten splits are ⚠️/❌ and most have this shape. The split is the finding, not a hedge. **14. (c)** Cosmetic and topical — three of the book's ten splits, because that is where the distance between what was measured and what was claimed is widest. **15. (b)** ✅ on a hard clinical outcome. It can be refined but is very rarely reversed, because the endpoint is not a proxy for the thing that matters — it is the thing that matters. **16. (b)** Downward. This is the phase 2 optimism effect. Intranasal oxytocin for autism and calcitonin for fracture risk are both recorded in this table as ⚠️/❌ downgrades that moved in exactly this direction. **17. (c)** Ten rows resolving to eight distinct claims, across four tiers: four ✅, two ⚠️, one 🔬, and one ❌ (the last being about compounded product equivalence rather than about the molecule). The gap between ten and eight is two claims that two different chapters rated independently — weight loss and cardiovascular event reduction, each in Chapters 5 and 8. Both pairs agree. **18.** The phrase is *with documented growth hormone deficiency*. ✅ for replacement in children and adults who have it; ❌ for administration to healthy adults who do not. A good answer names one of: mecasermin (✅, children with severe primary IGF-1 deficiency) against IGF-1 / IGF-1 LR3 (❌, healthy adults); or myostatin/follistatin inhibitors (⚠️, muscular dystrophy) against follistatin-344 (❌, healthy trained adults). The general pattern: ✅ or ⚠️ where there is a documented deficiency or disease, ❌ where healthy people want more of something they already have enough of. **19.** A good answer contains three elements. (i) The phrase specifies no scope — identity, purity, content, sterility, endotoxin, and residual solvents are separate determinations and most programs run two or three. (ii) A certificate describes a supplier-provided sample at a past moment, not the container in your hand. (iii) The ❌ attaches to the *inference* from "tested" to "is what the label says," not to testing itself, which is genuinely better than nothing. **20.** Right as a logical point: if nobody has looked, the claim has not been refuted, and the compound genuinely might work. Wrong as an argument, first because "might work" is the starting position every compound occupies before investigation, so arriving at it is not a result; and second because absence of evidence *is* weak evidence of absence when a search would likely have found something — for a compound circulating for twenty years in a market with real money in it, the persistent absence of a completed trial is itself informative. A strong answer also notes the tell: the argument is deployed almost exclusively where evidence is absent and never where it is present and negative. **21.** Both substitute a prior about the source for an examination of the evidence; they differ only in direction. Severe drift is harder to detect, because it feels like rigor from the inside, because it is right more often in a market full of nonsense, and because being wrong in the skeptical direction never feels like being wrong. Being right for the wrong reason is still not knowing. **22.** (i) Safety: a ✅ means efficacy is established and the safety profile is *characterized*, not benign — ziconotide, colistin, and botulinum toxin all carry ✅ and all carry serious managed risks; an ❌ means neither dangerous nor harmless, and for an evidence-absent ❌ the same absence usually applies to systematic safety data. (ii) You personally: every rating is population-level evidence, which is an input to a clinical decision rather than the decision. A ✅ in a population you are not in is not your ✅.